Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 734.9 USD -2.94% Market Closed
Market Cap: 696.7B USD

LLY's latest stock split occurred on Oct 16, 1997

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

The adjusted shares began trading on Oct 16, 1997. This was LLY's 4th stock split, following the previous one in Dec 21, 1995.

Last Splits:
Oct 16, 1997
2-for-1
Dec 21, 1995
2-for-1
May 1, 1989
2-for-1
Jan 30, 1986
2-for-1
Pre-Split Price
N/A
Post-Split Price
37.6772
Before
After
Last Splits:
Oct 16, 1997
2-for-1
Dec 21, 1995
2-for-1
May 1, 1989
2-for-1
Jan 30, 1986
2-for-1

Eli Lilly and Co
Stock Splits History

LLY Stock Splits Timeline
Oct 16, 1997
Oct 16, 1997
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
37.6772
Before
After
Dec 21, 1995
Dec 21, 1995
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
37.6772
Before
After
May 1, 1989
May 1, 1989
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
37.6772
Before
After
Jan 30, 1986
Jan 30, 1986
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
37.6772
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 15, 2025
Rover Metals Corp
F:4XO0
1-for-10
/10
0.0001 0.0005 EUR 0.05 0.05 EUR
Apr 15, 2025
S
Starbox Group Holdings Ltd
NASDAQ:STBX
1-for-14
/14
0.1426 1.9964 USD 1.8005 1.8005 USD
Apr 15, 2025
S
Scilex Holding Co
NASDAQ:SCLX
1-for-35
/35
0.1885 6.5975 USD 6.92 6.92 USD
Apr 15, 2025
Creative Media & Community Trust Corporation
NASDAQ:CMCT
1-for-25
/25
0.2057 5.1425 USD 5.24 5.24 USD
Apr 15, 2025
H
Hyungji Innovation and Creative Co Ltd
KOSDAQ:011080
549-for-451
x1.2172949002217
2210.0013 1815.502 KRW 2355 2355 KRW
Load More

Eli Lilly and Co
Glance View

Economic Moat
Wide
Market Cap
696.3B USD
Industry
Pharmaceuticals

Eli Lilly and Co. has long been a stalwart in the pharmaceutical industry, sculpting its trajectory through innovation and strategic acumen. Founded in 1876 by Colonel Eli Lilly, the company has grown from a small chemical firm into a global powerhouse in developing life-changing medications. Its headquarters in Indianapolis, Indiana, serve as a hub of research and development, where groundbreaking scientific exploration meets business strategy. Eli Lilly thrives on its core pillars of innovation in oncology, immunology, and diabetes care, relying on a deep commitment to scientific discovery and patient care. This emphasis allows it to consistently bring cutting-edge treatments to market, boosting its reputation as a leader in pharmaceuticals and maintaining a strong pipeline of drugs that drive future growth. The company's business model is principally built around creating proprietary medications that command premium pricing due to their uniqueness and effectiveness. This model sustains Eli Lilly's revenue through a dual approach: serving mature markets with established products and fueling growth with new launches. Patents on flagship drugs protect these revenue streams, allowing the company to invest substantially in research and development, which in recent years prioritizes personalized medicine and biotechnology. Collaborations with academic institutions and other corporations have also been pivotal, accelerating drug development and expanding Eli Lilly's reach across therapeutic areas. Overall, its ability to navigate regulatory frameworks and maintain robust sales and marketing strategies ensures its medications reach patients globally, securing its financial health and influence within the healthcare landscape.

LLY Intrinsic Value
375.29 USD
Overvaluation 49%
Intrinsic Value
Price
Back to Top